ClinicalTrials.gg
Status unknownNCT03485456Updated Oct 1, 2021

DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis

A Phase 1/2 interventional study of Tobramycin in Cystic Fibrosis, sponsored by University Medical Center Groningen. Status unknown at 1 site in Netherlands. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-10-01.

Sponsored by University Medical Center Groningen · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing tobramycin in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. Tobramycin · Cystic Fibrosis.

Planned enrollment
22nd of 25
10 · median 55
Started
2019
the only one that year
Phase 1/2
2 of 25
none open now
Registered
25th of 25
by date

Among the 25 studies testing tobramycin in Cystic Fibrosis, this one is the 22nd largest by planned enrollment, is the only one that started in 2019, is one of 2 in phase 1/2, and was the 25th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 25 studies testing tobramycin in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About tobramycin

Tobramycin: first FDA approval 1975 (NEBCIN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing tobramycin in Cystic Fibrosis as a file.
02

Study summary

The goal is to investigate the pharmacokinetic properties of dry powder tobramycin via the Cyclops® at different dosages in children with cystic fibrosis, together with the local tolerability.

Read the detailed description

Rationale: Cystic fibrosis is the most common life-shortening autosomal recessive disease among Caucasian populations. It is a chronic progressive disease causing deterioration of pulmonary function, and of general condition as well. Although it is a multisystem disease, the primary cause of death is respiratory failure, resulting from chronic pulmonary infection.

Pseudomonas aeruginosa is the predominant pathogen. The presence of P. aeruginosa in patients with CF is an unfavourable prognostic indicator and is associated with accelerated lung tissue destruction and loss of lung function, subsequently leading tot increased morbidity and mortality. Preventing, limiting and treating chronic infection with P. aeruginosa is therefore crucial in the management of CF, to improve survival and quality of life.

Currently most children with CF who are colonized with P. aeruginosa receive inhaled tobramycin every other month, mostly by use of a nebulizer. This delivery system however has several disadvantages. For example, the nebulisation itself and the cleaning of the nebulizer is time consuming. This places a high burden on a CF patient, especially for children, which will negatively influence compliance and quality of inhalation, thereby jeopardizing effective treatment. Therapy with a (disposable) dry powder inhaler (DPI) is less time consuming. Besides this, nebulisation brings the risk of auto-re-infection of the patient (contamination of nebulisation fluid and/or device). Other more technical disadvantages of nebulisation are a low lung deposition and pollution with tobramycin in the surrounding environment. With an efficient DPI, a three to six fold higher lung deposition compared to a nebulizer can be obtained. Nebulised tobramycin is used most in routine care, but sometimes a DPI is used, for example the Podhaler®. Although the dispersion behaviour of these dry powder systems is often good, the engineering processes make the products expensive, and the high excipient fractions make the inhaled powder doses high. Furthermore because these devices are not disposable, there is a risk of bacterial resistance development in the device. Next to this is the hygroscopic nature of tobramycin a risk for good dispersion when a used DPI is store inappropriately. In this situation powder residues in the inhaler become sticky or even liquefied when they absorb moisture from the air. There is one disposable DPI for tobramycin available, called the Cyclops®, but this DPI is not registered for children with CF yet. The investigators will therefore investigate dry powder tobramycin (DP tobramycin) in the Cyclops® in children with CF.

Objective: The main objectives are to investigate the pharmacokinetic properties of DP tobramycin via the Cyclops® at different dosages in children with CF, together with the local tolerability.

Study design: Single center, single ascending, single dose study.

Study population: 10 patients with CF, age 6 - 18 years.

Main study parameters/endpoints: The following pharmacokinetic parameters will be calculated: actual dose (dose minus remainder in inhaler after inhalation), AUC0-12 (area under the curve from 0 - 12 h), Cmax (maximum plasma concentration), Tmax (time to maximum plasma concentration), Ka (absorption rate constant), T1/2 el (terminal elimination half-life), CL/F (clearance following pulmonary administration (F= bioavailability)). Local tolerability of DP Tobramycin is determined by scoring adverse events, specifically coughing, and lung function measurement.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Target population of this study consists of children aged 6-18 years, because no information is available for inhalation of tobramycin using the Cyclops® in this population. Moreover, especially for children with CF a more easy to use and less time consuming treatment may improve their quality of life. Children participating in this study will receive instructions before using the DPI and their inspiratory flow will be tested. After each test dose serum samples will be collected with dry blood spot via a finger prick. To investigate safety, lung function tests will be performed before and 15, 30 and 90 minutes after inhalation and the occurrence of adverse events will be scored. Tobramycin is a registered drug for the treatment of chronic P. aeruginosa infection in CFpatients of 6 years and older. Inhalation of tobramycin is proven to be effective and safe in multiple studies. Dry powder tobramycin inhalation via the Cyclops® has been evaluated in adults with non-CF bronchiectasis. In this study a good drug dose - serum concentration correlation was obtained in adults, and the dry powder tobramycin inhalation via the Cyclops has been found safe with only mild tobramycin-related cough was reported once.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Dry powder inhalation
  • Tobramycin
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of CF and a positive sweat test or two CF-related mutations;
  • Age 6 - 18 years
  • Ability to breathe through a mouthpiece and to use the Cyclops
  • Ability to perform pulmonary function tests
  • Written (child and parents)

Exclusion criteria

Exclusion criteria:

  • Acute exacerbation of pulmonary infection
  • \< 60%
  • Subjects with known or suspected renal, auditory, vestibular of neuromuscular dysfunction, or with severe, active haemoptysis
  • History of adverse events on previous tobramycin or other aminoglycoside use
  • No concurrent use of cisplatin, cyclosporine, amphotericin B, cephalosporins, polymyxins, vancomycin and NSAID's
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Tobramycin

    Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin

    Drug: Tobramycin

Interventions

  • Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin

    Also known as: Tobramycin dry powder

06

What researchers measure

Primary outcomes

  1. AUC 0-12

    Area under the curve from 0 - 12 h

    Time frame: 0-12 hours after dry powder inhalation

Secondary outcomes

  1. Cmax

    maximum plasma concentration

    Time frame: 0-12 hours after dry powder inhalation

  2. Tmax

    Time to maximum plasma concentration

    Time frame: 0-12 hours after dry powder inhalation

  3. Ka

    Absorption rate constant

    Time frame: 0-12 hours after dry powder inhalation

  4. T 1/2 el

    Terminal elimination half-life

    Time frame: 0-12 hours after dry powder inhalation

  5. CL/F

    Clearance following pulmonary administration

    Time frame: 0-12 hours after dry powder inhalation

  6. Local tolerability

    Local tolerability determined by scoring adverse events, specifically coughing, and lung function

    Time frame: Before and 15, 30 and 90 minutes after inhalation

07

Study locations

1 of 1 sites recruiting
  • University Medical Center Groningen
    Groningen, Netherlands
    Recruiting
    • Anne Akkerman-Nijland, Drs. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Nov 2020, 17 months.

Of 26 phase 1/2 interventional studies under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2018
First posted
Apr 2, 2018
StartActual
May 29, 2019
Primary completionActual
Nov 13, 2020
CompletionEst.
Jan 1, 2022
Last update
Oct 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03485456
Responsible party
Onno Akkerman (Dr., University Medical Center Groningen) — Principal investigator
First posted
Apr 2, 2018
Start date
May 29, 2019
Primary completion
Nov 13, 2020
Completion
Jan 1, 2022 (estimated)
Last update
Oct 1, 2021

Study contacts

Anne M Akkerman-Nijland, MD
Contact
a.m.akkerman-nijland@umcg.nl
0031503616161
Onno Akkerman, PhD
Contact
o.w.akkerman@umcg.nl
Gerard Koppelman, Prof.
study chair · University Medical Center Groningen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tobramycin

Start the discussion